[go: up one dir, main page]

ES2525029T3 - Predicción del riesgo de sufrir episodios cardíacos adversos graves - Google Patents

Predicción del riesgo de sufrir episodios cardíacos adversos graves Download PDF

Info

Publication number
ES2525029T3
ES2525029T3 ES13179055.2T ES13179055T ES2525029T3 ES 2525029 T3 ES2525029 T3 ES 2525029T3 ES 13179055 T ES13179055 T ES 13179055T ES 2525029 T3 ES2525029 T3 ES 2525029T3
Authority
ES
Spain
Prior art keywords
macers
subject
treatment
risk
compared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13179055.2T
Other languages
English (en)
Inventor
James V. Snider
Eugene R. Heyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Critical Care Diagnostics Inc
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Application granted granted Critical
Publication of ES2525029T3 publication Critical patent/ES2525029T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Un método para seleccionar un tratamiento para un sujeto, método que comprende: la determinación de una puntuación de riesgo de sufrir un episodio cardíaco adverso grave (MACERS) para un sujeto basándose, al menos en parte, en la relación de un segundo nivel de gen soluble 2 expresado por estimulación del crecimiento (ST2) en el sujeto en un segundo momento (ST2 T1) con un primer nivel de ST2 soluble en el sujeto en un primer momento (ST2 T0), junto con un logaritmo natural ponderado de un nivel de la prohormona N-terminal del péptido natriurético de tipo cerebral (NT-proBNP) en el sujeto en un segundo momento (NP T1) de acuerdo con la siguiente fórmula: MACERS >= (ST2 T1/ST2 T0 + αln(NP T1), donde α es un factor de ponderación; la comparación de la MACERS con una MACERS de referencia; y la elección de: (a) hospitalización inicial, tratamiento continuo sobre pacientes hospitalizados o cateterismo cardíaco para un sujeto con una MACERS elevada en comparación con la MACERS de referencia, (2) un tratamiento alternativo para un sujeto que recibe un tratamiento y que presenta una MACERS elevada en comparación con la MACERS de referencia, o (3) tratamiento continuo o interrupción del tratamiento, tal como con el alta del hospital, para un sujeto que recibe un tratamiento y que presenta una MACERS disminuida en comparación con la MACERS de referencia.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
E13179055
26-11-2014
5
10
15
20
25
[0074] Para definir mejor la utilidad funcional de la relación ST2 combinado con un valor NT-proBNP se desarrolló una fórmula:
[0075] Esta fórmula se desarrolló evaluando el resultado como una función ABC ROC para un intervalo de coeficientes asociados con el término NT-proBNP. El resultado de esta serie de cálculos se muestra en la Figura
1.
[0076] El valor ABC máximo se consiguió con un coeficiente para a de 0,33 resultando en que la ecuación final es:
[0077] Al utilizar este algoritmo en una serie de cálculos comparando la sensibilidad, especificidad y riesgo relativo (eje lateral derecho) obtenemos el gráfico de la Figura 2.
[0078] En este gráfico el valor de puntuación que resulta en el máximo valor de riesgo relativo es 3,2. El análisis ROC de estos datos confirma que el valor de umbral óptimo es 3,3, ilustrado en la Figura 3. Además cabe destacar que el valor ABC utilizando esta puntuación es de 0,80 según se compara con el 0,77 para la relación ST2 y 0,72 para la relación NT-proBNP, que generó los siguientes valores ABC más altos.
[0079] Cuando se utiliza esta puntuación, en el valor de umbral de 3,2, para estratificar a los pacientes en esta cohorte que están en riesgo de padecer un episodio: un ingreso, un trasplante o la mortalidad, se consigue una clara distinción entre los pacientes con riesgo bajo y los pacientes con riesgo alto. Estos resultados se ilustran en la Tabla 4.
Tabla 4: Resumen de la estratificación de pacientes por el riesgo de sufrir episodios adversos en 1 año utilizando un punto de corte de la puntuación de 3,2.
Puntuación mediana
media
<3,2 >3,2 3,55 3,71
N 17 31
Episodio N 3 23
% Episodio 17,6 %
74,2 %
PPV
74,2 % NPV 82,4 %
RR 4,2
[0080] Al comparar directamente estos resultados con los resultados que utilizan sólo la relación ST2, mostrados en la Tabla 2, se ilustra que combinando la relación ST2 con un valor NT-proBNP todos los parámetros relevantes que representan la evaluación de predicción del riesgo son más fuertes; PPV, NPV y RR.
[0081] Para comparar los resultados de estratificación para el siguiente valor más fuerte, la relación NT-proBNP se resume en la Tabla 5. Los valores que utilizan la relación NT-proBNP son mucho más bajos que cuando se utiliza la relación ST2 o desde la fórmula que combina ST2 con NT-proBNP
Tabla 5: Resumen de la estratificación de pacientes por el riesgo de sufrir episodios adversos en 1 año utilizando la relación NT-proBNP
Relación NT-proBNP mediana media
<0,75 >0,75 0,74 0,83
N
24 24
Episodio N
10 16
% Episodio
41,7 % 66,7 %
PPV
66,7 %
NPV
58,3 %
12
imagen11
imagen12
imagen13
imagen14
E13179055
26-11-2014
imagen15
imagen16
[0103] El valor óptimo ROC a partir de este análisis fue 3,52. Como observamos utilizando los datos de la cohorte de péptidos (véase el Ejemplo I), la ROC de la fórmula de puntuación de riesgo de MACE óptima también fue 3,5 pero la mejor precisión de pronóstico (mortalidad) se alcanzó con un valor 3,2 en esa cohorte. Un diagrama de caja y bigotes básico (Figura 19) muestra una resolución clara entre el grupo de supervivientes y de
20 fallecidos, p<0,0001. Para comparar, un análisis de gráfico de caja y bigotes de ST2 R L:F es similar, con un p=0,0001 (Figura 20). También se observó utilizando los datos de la cohorte de péptidos que un análisis de matriz básico y un cálculo de riesgo relativo confirman que la puntuación de riesgo de MACE proporciona la predicción de mortalidad más precisa.
Tabla 16: Análisis de matriz y riesgo relativo de las variables de predicción de mortalidad más fuertes
25
30
ST2 R L:F
NTproBNP R L:F Puntuación de riesgo MACE
<0,85
≥0,85 <0,7 ≥0,7 <3,5 ≥3,5
N
76 31 49 58 65 42
N mortalidad
3 10 2 11 1 12
% mortalidad
3,9% 32,3% 4,1% 19,0% 1,5% 28,6%
PPV
32,3% 19,0% 28,6%
NPV
96,1 % 95,9% 98,5%
RR
8,2 4,6 18,6
[0104] Pese a que tanto la relación ST2 como la relación NTproBNP produjeron buenos valores de riesgo relativo, el riesgo relativo utilizando la puntuación de riesgo de MACE fue mucho mayor.
35 Conclusión
[0105] Según se determinó utilizando los datos de la cohorte de péptidos (Ejemplo 1) la fórmula de puntuación de riesgo de MACE descrita en el presente documento proporciona la mayor precisión de pronóstico, específicamente cuando el parámetro resultante es la mortalidad, según se determina por la ROC, la relación de riesgo y el cálculo de riesgo relativo. Existe una pequeña pero significativa diferencia entre los valores de umbral
17
imagen17
imagen18

Claims (1)

  1. imagen1
    imagen2
ES13179055.2T 2008-04-18 2009-04-17 Predicción del riesgo de sufrir episodios cardíacos adversos graves Active ES2525029T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4615808P 2008-04-18 2008-04-18
US46158P 2008-04-18

Publications (1)

Publication Number Publication Date
ES2525029T3 true ES2525029T3 (es) 2014-12-16

Family

ID=41199760

Family Applications (4)

Application Number Title Priority Date Filing Date
ES09731842.2T Active ES2443125T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves
ES16166093.1T Active ES2687401T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves
ES13179055.2T Active ES2525029T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo de sufrir episodios cardíacos adversos graves
ES14177846.4T Active ES2590213T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES09731842.2T Active ES2443125T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves
ES16166093.1T Active ES2687401T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14177846.4T Active ES2590213T3 (es) 2008-04-18 2009-04-17 Predicción del riesgo a sufrir episodios cardíacos adversos graves

Country Status (14)

Country Link
US (5) US8090562B2 (es)
EP (5) EP2269063B1 (es)
JP (6) JP5526122B2 (es)
AU (3) AU2009236109B2 (es)
CA (1) CA2720674A1 (es)
DK (4) DK2660599T3 (es)
ES (4) ES2443125T3 (es)
HK (3) HK1152750A1 (es)
HR (2) HRP20131100T1 (es)
HU (2) HUE029880T2 (es)
PL (4) PL2827152T3 (es)
PT (4) PT2660599E (es)
SI (4) SI3093663T1 (es)
WO (1) WO2009129454A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
HUE039881T2 (hu) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1L1RL-1, mint egy kardiovaszkuláris betegség-marker
PL2848938T3 (pl) 2006-04-24 2018-02-28 Critical Care Diagnostics, Inc. Ocena skuteczności leczenia u osobnika na podstawie poziomów ST2
WO2007143295A2 (en) * 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
JP5377289B2 (ja) 2006-05-01 2013-12-25 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心血管疾患の診断方法
DK2019965T3 (en) * 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
US9968266B2 (en) 2006-12-27 2018-05-15 Cardiac Pacemakers, Inc. Risk stratification based heart failure detection algorithm
PT2660599E (pt) 2008-04-18 2014-11-28 Critical Care Diagnostics Inc Predição do risco de eventos cardíacos adversos maiores
EP2353011B1 (en) * 2008-10-07 2020-03-04 B.R.A.H.M.S GmbH Biomarker for the prediction of first adverse events
US9561006B2 (en) * 2008-10-15 2017-02-07 The United States Of America As Represented By The Secretary Of The Navy Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival
US8417541B1 (en) * 2009-08-27 2013-04-09 Cerner Innovation, Inc. Multi-stage model for predicting probabilities of mortality in adult critically ill patients
US20130066212A1 (en) * 2009-09-25 2013-03-14 Volcano Corporation Device and Method for Determining the Likelihood of a Patient Having a Clinical Event or a Clinically Silent Event Based on Ascertained Physiological Parameters
EP3050901B1 (en) * 2010-04-09 2018-08-29 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
JP6134316B2 (ja) 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
EP3434260A1 (en) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
CN102830234A (zh) * 2012-08-10 2012-12-19 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
SG10201704311VA (en) 2012-08-16 2017-07-28 Critical Care Diagnostics Inc Methods for predicting risk of developing hypertension
RU2015110054A (ru) * 2012-08-21 2016-10-10 Критикал Кэа Дайэгностикс, Инк. Мультимаркерная стратификация риска
RU2510505C1 (ru) * 2012-11-15 2014-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ определения вероятности выраженной сердечной недостаточности в клинической картине инфаркта миокарда
GB201310290D0 (en) * 2013-06-10 2013-07-24 Univ Manchester Method for determining a probability of a major adverse cardiac event (MACE)
WO2015106081A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
WO2016140958A1 (en) * 2015-03-02 2016-09-09 Estes Edward Harvey Method and device to predict adverse cardiovascular events and mortality from an electrocardiogram-based validated risk score
EP3435846B1 (en) * 2016-04-01 2024-08-07 Cardiac Pacemakers, Inc. Multi-disease patient management
AT518560B1 (de) * 2016-04-18 2018-01-15 Trumpf Maschinen Austria Gmbh & Co Kg Biegebalken für eine Schwenkbiegemaschine
US11615891B2 (en) 2017-04-29 2023-03-28 Cardiac Pacemakers, Inc. Heart failure event rate assessment
JP7057995B2 (ja) 2017-10-03 2022-04-21 株式会社国際電気通信基礎技術研究所 哺乳動物におけるうつ病の病態プロファイルを検出するバイオマーカーとその利用
US20200074313A1 (en) * 2018-08-29 2020-03-05 Koninklijke Philips N.V. Determining features to be included in a risk assessment instrument
JP7043374B2 (ja) 2018-09-18 2022-03-29 株式会社日立製作所 多機能神経フィードバックシステム及び多機能神経フィードバック方法
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11551817B2 (en) 2020-01-14 2023-01-10 International Business Machines Corporation Assessing unreliability of clinical risk prediction
JP2024508975A (ja) * 2021-03-08 2024-02-28 サノフイ 心血管疾患

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (ja) 1992-12-14 1998-03-25 眞一 富永 ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1998007754A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. T1 receptor-like ligand ii
JP2001513641A (ja) 1997-02-28 2001-09-04 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｔ１／ｓｔ２−レセプターリガンド▲ｉｉｉ▼
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
DK1003501T3 (da) 1997-04-02 2005-07-18 Brigham & Womens Hospital Anvendelse af et middel til reduktion af risikoen for kardiovaskulær sygdom
EP0988552B1 (en) 1997-06-10 2010-11-24 Lpath, Inc. Methods for early detection of heart disease
CN1161609C (zh) 1997-09-11 2004-08-11 盐野义制药株式会社 哺乳类γ－BNP衍生物特异的免疫测定方法及其试剂盒
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB9827348D0 (en) * 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
AU2055300A (en) 1998-12-18 2000-07-03 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
EP1210117A2 (en) 1999-08-24 2002-06-05 Medicure International Inc. Compositons for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
JP2004506443A (ja) 2000-08-22 2004-03-04 ブライハム　アンド　ウィメンズ　ホスピタル　インコーポレーテッド 心血管状態の診断および処置
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
FI20010019L (fi) 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
HUE039881T2 (hu) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1L1RL-1, mint egy kardiovaszkuláris betegség-marker
WO2003100000A2 (en) 2002-05-24 2003-12-04 Tularik Inc. Amplification and overexpression of oncogenes
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US20040265926A1 (en) * 2002-11-21 2004-12-30 Leong Ng Bodily fluid markers of tissue hypoxia
US20070042978A1 (en) 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005043123A2 (en) 2003-10-31 2005-05-12 Queststar Medical, Inc. System and apparatus for body fluid analysis using surface-textured optical materials
CA2860272C (en) 2003-11-26 2017-12-19 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
CA2549236C (en) 2003-12-05 2017-06-13 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
US20060196817A1 (en) 2004-12-17 2006-09-07 Clearwater Systems Corporation Method and apparatus for treating fluids
JP4870686B2 (ja) 2005-01-24 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー 抗炎症剤の投与に関連する心血管リスクを評価するための心臓ホルモンの使用
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
PL2848938T3 (pl) 2006-04-24 2018-02-28 Critical Care Diagnostics, Inc. Ocena skuteczności leczenia u osobnika na podstawie poziomów ST2
WO2007143295A2 (en) 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
JP5377289B2 (ja) 2006-05-01 2013-12-25 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心血管疾患の診断方法
DK2019965T3 (en) 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
US20080233191A1 (en) 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
AU2008251801A1 (en) 2007-05-11 2008-11-20 The General Hospital Corporation Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
WO2009040133A1 (en) 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
PT2660599E (pt) 2008-04-18 2014-11-28 Critical Care Diagnostics Inc Predição do risco de eventos cardíacos adversos maiores
WO2010025393A2 (en) * 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
EP2347266B9 (en) 2008-11-11 2014-02-12 B.R.A.H.M.S GmbH Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm
WO2011060361A1 (en) 2009-11-13 2011-05-19 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
US8258456B2 (en) 2009-11-27 2012-09-04 Himax Imaging, Inc. Image sensor
EP3050901B1 (en) 2010-04-09 2018-08-29 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
US20130302841A1 (en) 2010-11-01 2013-11-14 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
US8615387B2 (en) * 2011-04-07 2013-12-24 Invensys Systems, Inc. Dynamic simulation of fluid filled vessels
JP6134316B2 (ja) 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
EP3434260A1 (en) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
SG10201704311VA (en) * 2012-08-16 2017-07-28 Critical Care Diagnostics Inc Methods for predicting risk of developing hypertension
RU2015110054A (ru) 2012-08-21 2016-10-10 Критикал Кэа Дайэгностикс, Инк. Мультимаркерная стратификация риска
US9665593B2 (en) * 2013-03-28 2017-05-30 International Business Machines Corporation Dynamically synching elements in file
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
WO2015106081A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
AU2009236109A1 (en) 2009-10-22
EP3378955A1 (en) 2018-09-26
EP2660599A1 (en) 2013-11-06
EP3093663A1 (en) 2016-11-16
JP2019105645A (ja) 2019-06-27
PT3093663T (pt) 2018-10-19
US20180233229A1 (en) 2018-08-16
SI2269063T1 (sl) 2014-01-31
HUE039963T2 (hu) 2019-02-28
HUE029880T2 (en) 2017-04-28
PT2660599E (pt) 2014-11-28
PL3093663T3 (pl) 2018-11-30
JP6484679B2 (ja) 2019-03-13
JP5526122B2 (ja) 2014-06-18
ES2687401T3 (es) 2018-10-25
DK3093663T3 (en) 2018-09-24
US9886553B2 (en) 2018-02-06
JP5873521B2 (ja) 2016-03-01
US8090562B2 (en) 2012-01-03
PT2827152T (pt) 2016-09-13
SI2660599T1 (sl) 2014-12-31
JP2021039108A (ja) 2021-03-11
EP3093663B1 (en) 2018-06-13
US20090264779A1 (en) 2009-10-22
SI3093663T1 (sl) 2018-10-30
AU2016200697B2 (en) 2018-01-04
DK2660599T3 (en) 2014-12-08
PL2660599T3 (pl) 2015-03-31
JP2017203784A (ja) 2017-11-16
JP2014178322A (ja) 2014-09-25
PL2269063T3 (pl) 2014-04-30
DK2827152T3 (en) 2016-09-12
PL2827152T3 (pl) 2016-12-30
JP6788050B2 (ja) 2020-11-18
AU2009236109B2 (en) 2015-11-05
HK1152750A1 (en) 2012-03-09
JP2011520098A (ja) 2011-07-14
HRP20131100T1 (hr) 2014-01-31
DK2269063T3 (da) 2013-12-02
HK1185658A1 (en) 2014-02-21
JP6200975B2 (ja) 2017-09-20
EP2269063B1 (en) 2013-08-21
ES2590213T3 (es) 2016-11-18
JP2016048272A (ja) 2016-04-07
EP2660599B1 (en) 2014-09-10
HRP20141056T1 (hr) 2015-01-02
AU2018202350A1 (en) 2018-04-26
US20130244236A1 (en) 2013-09-19
EP2827152A1 (en) 2015-01-21
US11170896B2 (en) 2021-11-09
CA2720674A1 (en) 2009-10-22
AU2016200697A1 (en) 2016-02-25
US9965593B2 (en) 2018-05-08
EP2269063A4 (en) 2011-05-04
EP2269063A2 (en) 2011-01-05
EP2827152B1 (en) 2016-06-08
WO2009129454A3 (en) 2010-01-28
WO2009129454A2 (en) 2009-10-22
PT2269063E (pt) 2013-11-27
US20150081224A1 (en) 2015-03-19
SI2827152T1 (sl) 2016-10-28
US20120065897A1 (en) 2012-03-15
HK1206419A1 (en) 2016-01-08
ES2443125T3 (es) 2014-02-17

Similar Documents

Publication Publication Date Title
ES2525029T3 (es) Predicción del riesgo de sufrir episodios cardíacos adversos graves
Orphanou et al. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments
Panagopoulou et al. NTproBNP: an important biomarker in cardiac diseases
Kelley et al. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure
Weissler-Snir et al. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge
Castillo et al. Brain natriuretic peptide: a potential marker for mortality in septic shock
Lupón et al. Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: a multicenter study
Zdravkovic et al. NT-proBNP for prognostic and diagnostic evaluation in patients with acute coronary syndromes
Poindron et al. T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients
ES2440740T3 (es) Utilización de SLIM-1 en la evaluación de la insuficiencia cardiaca
Seligman et al. Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia
Schuster et al. Fast manual long-axis strain assessment provides optimized cardiovascular event prediction following myocardial infarction
Ahmed et al. Disruption of desmin-mitochondrial architecture in patients with regurgitant mitral valves and preserved ventricular function
Ait Ali et al. Left ventricular dysfunction in repaired tetralogy of Fallot: incidence and impact on atrial arrhythmias at long term-follow up
Seoudy et al. HFA‐PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation
Fayad et al. The performance of prognostic models as predictors of mortality in patients with acute decompensation of cirrhosis
Volpe et al. Prediction of long‐term survival in chronic heart failure by multiple biomarker assessment: A 15‐year prospective follow‐up study
Maewal et al. Natriuretic peptide hormone measurement in acute coronary syndromes
Roubille et al. Routinely-feasible multiple biomarkers score to predict prognosis after revascularized STEMI
Leczycki et al. Heart failure risk predictions and prognostic factors in adults with congenital heart diseases
Koo et al. Evidence-Based determination of cut-off points for increased cardiac-surgery mortality risk with EuroSCORE II and STS: the best-performing risk scoring models in a single-centre australian population
Kaczyńska et al. B-type natriuretic peptide in acute pulmonary embolism
Nugroho The study of Triple-Dip La Nina phenomenon (2020-2023) and its impact on atmospheric dynamics and rainfall in the Indonesian region
Oravec et al. NT-proBNP levels in systemic sclerosis: association with clinical and laboratory abnormalities
Pu et al. Current perspectives of sudden cardiac death management in hypertrophic cardiomyopathy